Non-therapeutic use of hyperbranched dextrins as soothing agents

By using the high branch structure of hyperbranched dextrin, the prevention and mitigation of skin and oral mucosa reactions is solved, and effective soothing and protection of skin and oral mucosa is achieved, and suitable for sensitive skin and oral mucosa.

CN119095883APending Publication Date: 2024-12-06ROQUETTE FRERES SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033023.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-30
Filing Date
2023-03-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent or reduce skin and oral mucosal reactions, especially discomfort symptoms caused by cosmetic ingredients or environmental factors, such as fever, tightness, numbness and numbness.

Method used

Using hyperbranched dextrin as a soothing agent, through its high proportion of branched glycosidic bond structure, provides a non-therapeutic care method for preventing or reducing skin and oral mucosal reactions and is included in cosmetic compositions for improved compatibility and Soothing effect.

Benefits of technology

Hyperbranched dextrin significantly reduces and prevents skin and oral mucosa reactions caused by irritating substances, provides a long-term soothing effect, is suitable for sensitive skin and oral mucosa, and enhances the soothing and protective properties of cosmetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005074525220000261
    Figure BDA0005074525220000261
  • Figure BDA0005074525220000271
    Figure BDA0005074525220000271
  • Figure BDA0005074525220000272
    Figure BDA0005074525220000272
Patent Text Reader

Abstract

The present invention relates to hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, for use as soothing agents and in methods for preventing or reducing or eliminating responses of the skin and / or scalp and / or oral mucosa.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, for use as soothing agents and in methods for preventing or reducing or reversing skin reactions and oral mucosal reactions. Prior art

[0002] The skin and oral mucosa constitute both a living anatomical barrier and an exchange zone between the body and its environment, the effectiveness of which determines the maintenance of a good homeostatic balance. The skin consists of a surface layer composed of keratinized epithelial cells, the epidermis, and deeper layers, the dermis and subcutaneous tissue; each of these layers has specific properties that enable it to respond to and adapt to environmental conditions. The structure of the oral mucosa is similar to that of the skin, except that it does not have a surface layer of keratinized epithelial cells, but its surface is composed of non-keratinized epithelial cells.

[0003] Reactions of the skin (cutaneous) and oral mucosa can be triggered by the environment (e.g., cold, UV radiation, friction, food or beverages), as well as by certain products and active ingredients present in cosmetic compositions, dermocosmetic compositions, dermatological compositions, pharmaceutical compositions, medical compositions, veterinary compositions or household compositions. These skin reactions cause discomfort to the user's skin, scalp and oral mucosa, such as heating, tightness, tingling, itching and numbness. These skin reactions are more pronounced on sensitive skin and scalp and on sensitive mucosa. Cosmetic treatments can alleviate these discomforts associated with skin reactions and oral mucosal reactions by providing a soothing effect when applying the cosmetic product.

[0004] Therefore, there is a need to identify soothing compounds that can also prevent, reduce and soothe skin reactions and oral mucosal reactions produced by environmental or cosmetic products.

[0005] Certain C-glycoside derivatives are known for their soothing properties and have been incorporated into cosmetic compositions. One may cite those disclosed in document FR 2 902 998. Summary of the invention

[0006] The applicant has demonstrated that the Hyperbranched dextrin marketed as HM 06 relieved the sensation of heat and tightness caused by 20 hours of exposure of forearm skin to sodium lauryl sulfate (SLS).

[0007] The present invention relates to the use of hyperbranched dextrin as a soothing agent.

[0008] The present invention also relates to the use of hyperbranched dextrin for preventing, reducing or eliminating skin reactions and / or oral mucosal reactions.

[0009] The invention also relates to a method for non-therapeutic care of the skin and / or scalp and / or oral mucosa, which method comprises applying hyperbranched dextrin to the skin and / or scalp and / or oral mucosa.

[0010] The present invention also relates to a cosmetic composition comprising a hyperbranched dextrin in a cosmetically acceptable medium.

[0011] These compositions are suitable for all skin types and are particularly suitable for sensitive skin and / or scalp and sensitive oral mucosa. DETAILED DESCRIPTION

[0012] Hyperbranched dextrin

[0013] According to a first embodiment, the dextrins useful for non-therapeutic uses for the purposes of the present application are hyperbranched dextrins.

[0014] By "dextrins", the applicant means the glucose polymers obtained from granular starch by thermal conversion by the action of acids, usually in a generally dry environment, that is to say, on a dry solid granular form containing residual moisture imposed by the physical equilibrium conditions at a given temperature and pressure. Thus, maltodextrins and pyrolyzed dextrins, when modified to be branched, belong to the general family of dextrins that can be used in the present invention.

[0015] In the context of the present invention, by "dextrins", the applicant also means glucose polymers derived from the acid or enzymatic liquefaction or hydrolysis of starch, which polymers, when further chemically or enzymatically modified, in particular by branching enzymes, to have glycosidic bonds between the anhydroglucose molecules, are often referred to as "maltodextrins", "starch hydrolysates" or "glucose syrups", whose properties differ significantly from those of the starch from which they are derived. Thus, maltodextrins, starch hydrolysates, glucose syrups and thermolyzed dextrins belong to the general family of dextrins that can be used in the present invention, as they differ from the starch from which they are derived in terms of carbohydrate bonds by containing "atypical" bonds.

[0016] By "hyperbranched dextrins", the applicants mean "dextrins" having glycosidic bonds between anhydroglucose molecules, the nature and amount of these glycosidic bonds being significantly different from those of the starch from which the hyperbranched dextrins are naturally composed. Hyperbranched dextrins have naturally occurring glycosidic bonds between anhydroglucose molecules, i.e. 1-6 bonds, but in greater amounts, and also have glycosidic bonds that are not naturally present in starch, called "atypical" bonds, i.e. 1-3 bonds and 1-2 bonds. Thus, hyperbranched dextrins are dextrins having a high proportion of branched glycosidic bonds relative to the total glycosidic bonds present in the dextrin. The term "hyperbranched" may also be replaced by "highly branched".

[0017] By "high proportion", we mean that the proportion of branched glycosidic bonds is greater than or equal to 5% of the sum of branched glycosidic bonds and linear glycosidic bonds, preferably greater than or equal to 10%, more preferably greater than or equal to 20%, more preferably greater than or equal to 30%, more preferably greater than or equal to 40%, more preferably greater than or equal to 50%. Branched glycosidic bonds are bonds that produce a higher proportion of non-linear chains than the normal value for natural starch. The glycosidic bonds that produce non-linear chains are 1-6, 1-3 and 1-2 glycosidic bonds, as shown in Figure 1 [Figure 1]. 1-3 bonds and 1-2 bonds are atypical glycosidic bonds. The normal values ​​of these bonds in natural starch are as follows: 1-6 bonds are about 5%, 1-2 bonds and 1-3 bonds are about 0%. The rest consists of 1-4 glycosidic bonds, that is, about 95%. 1-4 bonds are bonds that produce linear bonds.

[0018] For 1-6 glycosidic bonds, the characteristic values ​​of the hyperbranched dextrins that can be used in the present invention are the following values: greater than 5% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably greater than or equal to 10% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, more preferably greater than or equal to 12% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, and most preferably greater than or equal to 15% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

[0019] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 5%, preferably at least 10%, preferably at least 12%, preferably at least 15% 1-6 glycosidic bonds relative to the sum of α1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

[0020] For 1-2 and 1-3 glycosidic bonds, values ​​greater than 1% based on the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably greater than or equal to 5% based on the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, and more preferably greater than or equal to 10% based on the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds can be used in the present invention.

[0021] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 1%, preferably at least 5%, preferably at least 10%, preferably at least 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

[0022] According to one embodiment, the hyperbranched dextrin comprises at least 1%, preferably at least 5%, preferably at least 10%, preferably at least 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

[0023] For 1-4 glycosidic bonds, values ​​of less than 70%, preferably less than 60%, preferably less than 50% based on the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, and preferably between 42% and 50% based on the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds can be used in the present invention.

[0024] Thus, according to one embodiment, the hyperbranched dextrin comprises at most 70%, preferentially at most 50%, 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

[0025] Preferably, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has a 1-6 glycosidic bond content based on the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds of between 5% and 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and most preferably between 15% and 20%.

[0026] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has:

[0027] - 5% to 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and most preferably between 15% and 20% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0028] - 42% to 50% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0029] - 1% to 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0030] - 1% to 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

[0031] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has:

[0032] - at least 5% of 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0033] Preferably at least 10%, more preferably at least 12%, and most preferably at least 15%,

[0034] - no more than 70% of 1-4 glycosidic bonds, preferably no more than 60% and most preferably no more than 50% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0035] - at least 1% of 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0036] Preferably at least 5%, more preferably at least 10%, and most preferably at least 20%,

[0037] - at least 1% of 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0038] Preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

[0039] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has:

[0040] - 5% to 40%, preferably 10%, relative to the sum of 1-2 keys, 1-3 keys, 1-4 keys and 1-6 keys

[0041] to 30%, more preferably 12% to 22%, and most preferably 15% to 20% 1-6 glycosidic bonds,

[0042] - 42% to 70%, preferably 42% to 60%, of 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0043] - 1% to 20%, preferably 1%, relative to the sum of 1-2 keys, 1-3 keys, 1-4 keys and 1-6 keys

[0044] to 10%, more preferably 5% to 15%, and most preferably 5% to 10% 1-3 glycosidic bonds,

[0045] - 1% to 20%, preferably 1%, relative to the sum of 1-2 keys, 1-3 keys, 1-4 keys and 1-6 keys

[0046] 5% to 10%, more preferably 5% to 15%, and most preferably 5% to 10% 1-2 glycosidic bonds.

[0047] Besides the preparation of dextrins using the well-known thermal conversion methods applied to granular starch, that is, by using acid on granular starch, typically at elevated temperature in a dry environment, these atypical branch bond contents in starch can also be obtained by the action of so-called "branching" or "re-branching" enzymes on liquefied starch (such as maltodextrins, starch hydrolysates or glucose syrups), wherein the liquefied starch is optionally previously or subsequently hydrogenated.

[0048] Thus, these atypical linkage contents may be obtained by the action of "branching" or "re-branching" enzymes on liquefied starch and / or may be obtained by the action of acids on granular or liquefied starch in a drying medium, typically at elevated temperatures.

[0049] The 1-2, 1-3, 1-4 and 1-6 glycosidic bond contents can be determined using the conventional methylation technique described in HAKOMORI, S., 1964, J. Biochem., 55, 205. "A rapid Permethylation of Glycolipid, and Polysaccharide Catalyzed by Methylsulfinyl Carbanion in Dimethyl Sulfoxide". This method makes it possible to chemically characterize glycosidic bonds by distinguishing free OH groups from bonded groups. This is a destructive method that includes the steps of methylation, hydrolysis, reduction with NaBD4, acetylation and mass spectrometry.

[0050] According to one embodiment, the number average molecular weight Mn of the hyperbranched dextrin is less than or equal to 10,000 g / mol, preferably less than or equal to 4,500 g / mol, more preferably between 1,000 g / mol and 3,500 g / mol, even more preferably between 1,500 g / mol and 3,500 g / mol, most preferably between 1,800 g / mol and 3,200 g / mol.

[0051] According to one embodiment, the polynomial index of the hyperbranched dextrin, i.e. the ratio of the weight average molar mass to the number average molar mass (denoted as IP) is less than or equal to 15, preferably less than or equal to 10, more preferably less than or equal to 5, and most preferably less than or equal to 3.

[0052] Mn, Mw and IP values ​​were measured by size exclusion chromatography based on the selective retention of solute molecules due to their penetration or non-penetration into the pores of the stationary phase. The size exclusion chromatography columns used were PSS SUPREMA 100 and PSS SUPREMA 1000, which were connected in series and coupled to a light scattering detector.

[0053] According to one embodiment, the hyperbranched dextrin has a reducing sugar content of less than or equal to 20%, preferentially less than or equal to 15%, more preferentially less than or equal to 10%, even more preferentially less than or equal to 6%, and most preferentially less than or equal to 3%, relative to the total mass of the hyperbranched dextrin. The reducing sugar content is expressed as glucose, by weight relative to the dry weight of the analyzed product, determined by the BERTRAND method.

[0054] According to one embodiment, the hyperbranched dextrins useful in the present invention have a relatively high content of residual 1-4 glycosidic bonds. The content of 1-4 glycosidic bonds is between 42% and 50% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, and the content of 1-6 glycosidic bonds is between 12% and 22% based on the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds. Preferentially, the hyperbranched dextrins useful in the present invention have a 1-4 / 1-6 glycosidic bond ratio between 1.9 and 4.2, particularly between 2.3 and 3.5.

[0055] According to one embodiment, in the hyperbranched dextrins that can be used in the present invention, the content of 1-3 glycosidic bonds is between 1% and 10% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, and the content of 1-4 glycosidic bonds is between 42% and 50% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds. Preferentially, the hyperbranched dextrins that can be used in the present invention have a 1-4 / 1-3 glycosidic bond ratio between 0.02 and 0.24, in particular between 0.1 and 0.2. According to one embodiment, in the hyperbranched dextrins that can be used in the present invention, the content of 1-2 glycosidic bonds is between 1% and 10%, and the content of 1-4 glycosidic bonds is between 42% and 50%. Preferentially, the hyperbranched dextrins that can be used in the present invention have a 1-4 / 1-2 glycosidic bond ratio between 0.02 and 0.24, in particular between 0.1 and 0.2.

[0056] According to one embodiment, the hyperbranched dextrins useful in the present invention have:

[0057] - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0058] - a reducing sugar content less than or equal to 20% relative to the total mass of the hyperbranched dextrin, - a multiplicity index less than or equal to 15,

[0059] - and a number average molecular weight Mn less than or equal to 4500 g / mol.

[0060] According to one embodiment, the hyperbranched dextrins useful in the present invention have:

[0061] - 10% to 30% of 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0062] - 42% to 70% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0063] - a reducing sugar content less than or equal to 10% relative to the total mass of the hyperbranched dextrin,

[0064] - a polynomial index less than or equal to 10,

[0065] - and a number average molecular weight Mn between 1000 and 3500 g / mol.

[0066] According to one embodiment, the hyperbranched dextrins useful in the present invention have:

[0067] - 12% to 22% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0068] - 42% to 50% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0069] - 1% to 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0070] - 1% to 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0071] - a reducing sugar content less than or equal to 6% relative to the total mass of the hyperbranched dextrin,

[0072] - a polynomial index less than or equal to 5,

[0073] - and a number average molecular weight Mn between 1500 and 3000 g / mol.

[0074] Hyperbranched dextrins that can be used in the present invention are commercially available, such as of" FM 06", FM 10" and FM15S" product, or Tate & Lyle's " Solublefiber” product series.

[0075] With the name " Polydextrose" was purchased from Tate & Lyle or under the name Other commercial products available from Cargill are hyperbranched polysaccharides or oligosaccharides which, as such or after possible hydrogenation, are conceivable to have similar soothing properties to the hyperbranched dextrins disclosed in this application.

[0076] Hyperbranched Hydrogenated Dextrin

[0077] According to a second embodiment, the dextrins useful for non-therapeutic purposes for the purposes of the present application are hyperbranched hydrogenated dextrins. Such dextrins can be obtained by subjecting the hyperbranched dextrins for the purposes of the present application to hydrogenation, or by applying a "branching" or "rebranching" process to a previously hydrogenated dextrin. The hydrogenation can be achieved, for example, by contacting an aqueous solution of the hyperbranched dextrin with hydrogen in the presence of a catalyst such as Raney nickel.

[0078] Additional features can be added to the embodiments of the hyperbranched dextrins set forth above, namely, a reducing sugar content of less than or equal to 5 wt%, preferably less than or equal to 3 wt%, more preferably less than or equal to 2 wt%, more preferably less than or equal to 1 wt%, more preferably less than or equal to 0.5 wt%, and most preferably less than or equal to 0.15 wt%.

[0079] According to one embodiment, the hyperbranched hydrogenated dextrins useful in the present invention have:

[0080] - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0081] - a reducing sugar content less than or equal to 4% relative to the total mass of the hyperbranched dextrin,

[0082] - a polynomial index less than or equal to 15,

[0083] - and a number average molecular weight Mn less than or equal to 4500 g / mol.

[0084] According to one embodiment, the hyperbranched hydrogenated dextrins useful in the present invention have:

[0085] - 10% to 30% of 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0086] - 42% to 70% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0087] - a reducing sugar content less than or equal to 3% relative to the total mass of the hyperbranched dextrin,

[0088] - a polynomial index less than or equal to 10,

[0089] - and a number average molecular weight Mn between 1000 and 3500 g / mol.

[0090] According to one embodiment, the hyperbranched hydrogenated dextrins useful in the present invention have: - 12% to 22% of 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0091] - 42% to 50% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0092] - 1% to 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0093] - 1% to 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds,

[0094] - a reducing sugar content less than or equal to 2% relative to the total mass of the hyperbranched dextrin,

[0095] - a polynomial index less than or equal to 5,

[0096] - and a number average molecular weight Mn between 1500 and 3000 g / mol.

[0097] Hyperbranched hydrogenated dextrins useful in the present invention are commercially available, such as Roquette's " HM06”.

[0098] Soothing Agents

[0099] The present invention is directed to the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, as demulcents.

[0100] Soothing agents are agents that prevent the onset of skin reactions and / or oral mucosal reactions, or reduce the intensity of these reactions or eliminate them.

[0101] Thus, according to one embodiment, the present invention relates to the non-therapeutic use of hyperbranched dextrins, preferentially hyperbranched hydrogenated dextrins, as soothing agents for skin reactions and / or oral mucosal reactions.

[0102] "Skin" means the skin, that is, the external covering of the human and vertebrate body, including the human scalp. Skin reactions cause discomfort to the user's skin and scalp. Skin reactions include warmth, tightness, tingling, numbness and itching. These reactions are non-pathological skin reactions.

[0103] Thus, according to one embodiment, the present invention relates to the non-therapeutic use of hyperbranched dextrins, preferentially hyperbranched hydrogenated dextrins, as soothing agents for cutaneous reactions of the skin and / or scalp.

[0104] According to one embodiment, the skin reaction is selected from the group consisting of warmth, tightness, tingling, numbness and itching.

[0105] "Oral mucosa" refers to the lips, tongue, tongue base, gums, inner surfaces of cheeks and lips, palate, and soft palate of humans and vertebrates.

[0106] The oral mucosal reaction causes discomfort in the lips, gums, inner cheeks or palate. The oral mucosal reactions include heat, burning, warmth, tightness, tingling, numbness and itching. According to one embodiment, the oral mucosal reaction is selected from burning, tingling or numbness.

[0107] These skin reactions are increased in individuals with sensitive skin or scalp. However, unlike allergic skin, this reactivity is not the result of an immunological process. Sensitive skin is defined by a specific reactivity. This skin reactivity is usually translated into the manifestation of previously defined discomfort signs, such as heat, tightness, tingling, numbness and itching. These skin reactions may be in response to contact with triggering elements. These skin reactions can occur on all skin types, but are more frequent on skin in a hypersensitive state represented by the term "sensitive skin", which corresponds to a skin state with increased sensitivity to external stimuli, that is, a sensitivity greater than the population average, or greater than the normal value for an individual.

[0108] "Sensitive scalp" refers to a scalp that is essentially triggered by local factors such as friction, soaps, surfactants, hard water with a high lime content, shampoos or lotions to produce itching and / or tingling and / or warming sensations. These sensations are sometimes also triggered by factors such as the environment, emotions and / or food. Scalp erythema, excessive sebum secretion and dandruff are often associated with the above signs.

[0109] According to one embodiment, the skin reactions are skin reactions of sensitive skin and scalp.

[0110] The term "sensitive oral mucosa" refers to oral mucosa that exhibits increased sensitivity compared to the average sensitivity of a population or compared to the normal sensitivity of an individual. Such sensitivity may be manifested by contact with surfactants (such as sodium lauryl sulfate), alcohols (such as ethanol), whitening agents (such as peroxides), or active ingredients or essential oils used in mouthwash, gel or toothpaste compositions.

[0111] According to one embodiment, the skin reaction and the oral mucosal reaction are induced by endogenous or exogenous stress.

[0112] These skin reactions can be induced by exogenous stressors such as

[0113] - Chemical substances or ingredients of preparations,

[0114] - mechanical aggression selected from friction, shaving, cuts, micro-cuts, depilation, abrasion, scrubbing, frequent washing, hard water with a high lime concentration,

[0115] - Environmental factors such as pollution, UV rays and exposure to sunlight,

[0116] - Selected from excessive exposure to the sun and thermal attacks from sources of heat or cold

[0117] - Foods and beverages that are abrasive or chemically aggressive to the oral mucosa.

[0118] Endogenous factors (such as hormone secretion, age, stress, sweating, etc.) can also induce skin or oral mucosal reactions.

[0119] Prevent, reduce or eliminate skin reactions and / or oral mucosal reactions

[0120] The present invention also relates to the non-therapeutic use of hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for preventing or reducing or eliminating skin reactions and / or oral mucosal reactions.

[0121] According to one embodiment, the skin reaction is selected from the group consisting of warmth, tightness, tingling, numbness and itching.

[0122] According to one embodiment, the oral mucosal reaction is selected from the group consisting of burning, warmth, tightness, tingling, numbness and itching.

[0123] Preventing a skin reaction or an oral mucosal reaction means preventing the onset of one or more skin reactions or oral mucosal reactions, delaying the onset of one or more skin reactions or oral mucosal reactions, and preventing the worsening of one or more skin reactions or oral mucosal reactions.

[0124] Reduction of skin reactions or oral mucosal reactions refers to a reduction in one or more skin reactions or oral mucosal reactions. For example, reduction of skin reactions refers to a reduction in the intensity of heat, tightness, tingling, numbness and itching. For example, reduction of oral mucosal reactions refers to a reduction in the intensity of heat, burning, tightness, tingling, numbness, itching, especially when brushing teeth, and a reduction in the intensity of dry mouth, nausea and retching.

[0125] The disappearance of a skin reaction or an oral mucosal reaction refers to the absence of one or more skin reactions or oral mucosal reactions.

[0126] According to one embodiment, the skin and scalp is sensitive skin and scalp.

[0127] According to one embodiment, the skin reaction and the oral mucosal reaction are induced by an endogenous or exogenous stress as previously defined.

[0128] Cosmetic method

[0129] The invention also relates to a method for non-therapeutic care of the skin and / or scalp and / or oral mucosa, which method comprises applying a hyperbranched dextrin, preferably a hyperbranched hydrogenated dextrin, to the skin and / or scalp and / or oral mucosa.

[0130] The hyperbranched dextrins can be applied in the form of cosmetic compositions comprising them.

[0131] According to one embodiment, the hyperbranched dextrins or the cosmetic compositions comprising them are applied to the area to be soothed of an individual showing one or more skin reactions or oral mucosal reactions, and optionally kept in contact for several minutes or hours, and optionally rinsed off. As a result, the method can be carried out during or after the stimulation and can be repeated or renewed as often as necessary over a period ranging from a few days to several months or even several years.

[0132] Thus, according to one embodiment, the method comprises applying hyperbranched dextrins or cosmetic compositions comprising them to the skin and / or scalp and / or oral mucosa showing one or more skin reactions or oral mucosal reactions.

[0133] According to one embodiment, the method comprises a further step, wherein the compound is brought into contact with the skin and / or scalp and / or oral mucosa.

[0134] According to one embodiment, the method comprises an additional washing step.

[0135] Alternatively, the hydrogenated hyperbranched dextrins or the cosmetic compositions comprising them may be applied prior to applying the cosmetic or dermatological treatment.

[0136] According to one embodiment of the invention, such a preventive method is used in a cosmetic or dermatological pretreatment to prevent the onset of one or more skin reactions and / or oral mucosal reactions that may occur during exposure to cold, heat, sunlight, sources of pollution, food, etc., or during the application of a subsequent cosmetic or dermatological treatment (such as the application of a cosmetic or dermatological composition comprising one or more irritants), coloring, bleaching, perming, straightening, peeling, anti-rosacea treatment, etc.

[0137] Therefore, the present invention also relates to a non-therapeutic skin and / or scalp and / or oral mucosa care method comprising at least two steps: a first pretreatment step aimed at preventing the occurrence of one or more skin reactions and / or oral mucosal reactions and which comprises applying hyperbranched dextrins or cosmetic compositions containing them to the skin and / or scalp and / or oral mucosa; and a second step, after said first step, of applying a cosmetic or skin treatment.

[0138] According to one embodiment of the present invention, hyperbranched dextrins or cosmetic compositions comprising them may be applied when endogenous and / or exogenous stress is expected.

[0139] Endogenous and / or exogenous stresses were defined as previously.

[0140] Cosmetic composition

[0141] Hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, can be incorporated into cosmetic compositions.

[0142] Therefore, the present invention also relates to a cosmetic composition comprising a hyperbranched dextrin and a cosmetically acceptable medium.

[0143] "Cosmetically acceptable" is understood to mean a medium which has no harmful side effects and in particular does not produce redness, inflammation, heat, tightness or tingling which is unacceptable to the user of the cosmetic product under normal conditions of use. Thus, the medium is compatible with the skin, scalp and oral mucosa of humans and animals.

[0144] According to one embodiment, the compounds according to the invention may be incorporated into a cosmetic composition containing one or more compounds liable to cause skin irritation.

[0145] According to one embodiment, the hyperbranched dextrins or the cosmetic compositions comprising them are applied to non-pathological skin showing one or more non-pathological skin reactions.

[0146] According to one embodiment, the content of hyperbranched dextrin is between 0.1% and 50% by weight, preferentially between 0.5% and 20% by weight, more preferentially between 1% and 10% by weight, and most preferentially between 1.5% and 7.5% by weight, and typically between 2% and 5% by weight, relative to the total weight of the composition.

[0147] Application form

[0148] The cosmetic composition according to the invention may be in any pharmaceutical form usually used for topical application, such as an aqueous, hydroalcoholic or oily solution, an emulsion-type or serum-type dispersion or solution, a milky emulsion of liquid or semi-liquid consistency (obtained by dispersing a fat phase in an aqueous phase (O / W) or vice versa (W / O)), or a soft, semi-solid or solid suspension or emulsion such as a cream-type emulsion, an aqueous or anhydrous gel, an anhydrous composition, a solid composition, a microemulsion, a microcapsule, a microparticle, or an ionic and / or non-ionic vesicular dispersion. For the purposes of the present invention, "topical application" means application to a body surface, such as the skin or a mucous membrane.

[0149] These compositions are prepared according to conventional methods known to those skilled in the art.

[0150] The composition, when applied to the skin, may be fluid to some extent and have the appearance of a cream, emulsion or microemulsion, ointment, milk, lotion, serum, paste, foam, mask, fluid, balm, oil, gel, unguent, mouthwash, toothpaste, colloidal paste. The composition may optionally be applied to the skin in aerosol form. The composition may also take a solid form, for example in the form of a stick or patch, or in the form of a dry soap or cleansing stick.

[0151] The composition can be used as a skin care product, in particular a skin care product for leave-on applications, such as a day or night cream for facial skin and / or body skin, as a cleanser, as a makeup product, as a deodorant, as a shaving product, as an aftershave product, as an aftersun product, as a sunscreen product, as a lip balm to protect the lips from the cold and / or the sun and / or the wind, etc. The composition can also be used as a rinse-off skin care product.

[0152] The composition according to the invention may also be a scalp and hair care composition, in particular in the form of a medicament for rinse-off application, such as a shampoo, hair conditioner, hair mask, serum, foam, balm, cream, spray, conditioner, hair serum, hair milk, mousse, balm, cream, spray, conditioner, hair serum, hair milk, and in the form of a treatment lotion, dye composition, coloring shampoo, permanent wave composition, anti-hair loss lotion or gel, antiparasitic shampoo, conditioner, etc. The composition according to the invention may also be a scalp and hair care composition, in particular in the form of a leave-on medicament.

[0153] Preparation ingredients

[0154] The cosmetic composition according to the present invention may further comprise a solvent selected based on the various ingredients and application forms.

[0155] According to one embodiment, the composition according to the invention may comprise an aqueous phase comprising water and, optionally, one or more water-miscible organic solvents.

[0156] The term "water-soluble solvent" refers to a compound that is liquid at room temperature and miscible with water (miscibility in water greater than 50% by weight at 25°C and atmospheric pressure).

[0157] The water-soluble solvents that can be used in the compositions according to the invention may be volatile.

[0158] Among the water-soluble solvents that may be used in the composition according to the invention, mention may be made of monoalcohols having 1 to 5 carbon atoms, such as ethanol and isopropanol, C3-C4 ketones and C2-C4 aldehydes, and polyols, such as glycerol or glycerol, sorbitol or isosorbide.

[0159] In addition to the hyperbranched dextrins, the cosmetic composition may also contain:

[0160] - One or more wetting agents

[0161] The wetting agent will be selected from esters of polyols and / or fatty acids and esters of polyethylene glycol.

[0162] "Polyol" is understood to mean any molecule having at least two free hydroxyl (-OH) groups in its structure. These polyols are preferably liquid at room temperature (25°C).

[0163] Typically the polyol is selected from the group consisting of maltitol, mannitol, xylitol, erythritol, sorbitol, isosorbide, glycerol, glucose, sucrose, polydextrose, hydrogenated glucose syrup, dextrin, maltodextrin, glucose syrup and mixtures thereof.

[0164] Examples include: Beautéby PO 071 (INCI: Sorbitol), Beautéby PO 260 (INCI: mannitol), Beautéby PO 370 (INCI: Xylitol), Beautéby PO 455 (INCI: Hydrogenated starch hydrolysate), Beautéby PO 500 (INCI: ISOSORBIDE), all of which are sold by ROQUETTE; Glycerin (INCI: GLYCERYL) sold by COOPER; Propylene glycol (INCI: PROPYLENE GLYCOL) sold by COOPER; Butylene glycol (INCI: 1,3-BUTYLENE GLYCOL).

[0165] Among the esters of fatty acids and polyethylene glycol, mention may be made of the product sold under the name Glucamate SSE-20 (INCI: PEG-20 Methyl Glucose Sesquistearate) by the company LUBRIZOL ADVANCED MATERIALS, Inc.

[0166] The composition comprises from 0.5% to 25% by weight of one or more wetting agents, preferably from 1% to 15% and even more preferably from 2% to 10% by weight of polyol relative to the total weight of the composition.

[0167] - One or more oils

[0168] For the purposes of the present invention, "oil" is understood to mean a compound that is liquid at room temperature (25° C.) and, when introduced in an amount of at least 1% by weight into water at 25° C., is not soluble in water at all or is soluble in water to an extent of less than 10% by weight relative to the weight of the oil introduced into the water. According to one embodiment, the oil will be chosen from volatile oils, non-volatile oils and mixtures thereof. Preferably, these oils are vegetable oils or oils of vegetable origin.

[0169] The term "non-volatile oil" refers to an oil that remains on the skin, scalp or oral mucosa for at least several hours at room temperature and atmospheric pressure and has a specific viscosity of less than 10 -3 Oil with a vapor pressure of mmHg (0.13Pa).

[0170] Among the non-volatile oils, mention may be made of fatty acid esters such as cetearyl isononanoate, isotridecyl isononanoate, isostearyl isostearate, isopropyl isostearate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-hexyldecyl laurate, 2-octyldecyl palmitate, 2-octyldodecyl myristic acid or lactate, 2-diethylhexyl succinate, diisostearyl malate, triacetin, tricaprin, caprylic / capric triglyceride, a mixture of cococaprylate and caprylic acid. Benzoates of C12 to C15 alcohols, glycol esters such as butylene glycol cocoate, glyceryl triisostearate, tocopheryl acetate, higher fatty acids (such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid or isostearic acid), higher fatty alcohols (such as oleyl alcohol, vegetable oils such as avocado oil, camellia oil, hazelnut oil, tsubaki oil, cashew oil, argan oil, soybean oil, grape seed oil, sesame oil, corn oil, wheat germ oil, rapeseed oil, sunflower oil, cottonseed oil, jojoba oil, peanut oil, macadamia oil, sweet almond oil, olive oil) and mixtures thereof.

[0171] These non-volatile oils may also be hydrocarbon or silicone type oils, such as paraffin oil, squalane, petroleum jelly, dimethicone, and mixtures thereof.

[0172] According to one embodiment, the non-volatile oil is chosen from stearic acid, jojoba oil (INCI: Simmondsiachinensis Seed Oil), grape seed oil (INCI: Vitis vinifera Seed Oil), macadamia oil (INCI: Macadamia ternifolia Seed Oil), refined oleic sunflower oil (Helianthus annuus Seed Oil), a mixture of caprate and coco-caprylate such as the product Miglyol Coco 810 (INCI: Coco-Caprylate / Caprate), sweet almond oil (INCI: Prunus Amygdalus Dulcis Oil), sesame oil (INCI: Sesame (Sesamumindicum) Seed Oil).

[0173] Volatile oil is intended to mean an oil that is capable of evaporating from the skin in less than one hour at room temperature and atmospheric pressure. The volatile oil may, for example, be chosen from silicone oils or short-chain fatty acid triglycerides in order to reduce greasiness.

[0174] According to one embodiment, the oil is present in a content ranging from 0.5% to 70% by weight, preferably from 1% to 60% by weight, preferably from 2% to 50% by weight, preferably from 5% to 40% by weight, preferably from 5% to 30% by weight relative to the total weight of the composition.

[0175] - one or more waxes and / or one or more pasty compounds .

[0176] "Wax" is intended to mean a fatty substance with a reversible liquid-solid state change and with a melting point greater than 25°C, generally between 30°C and 90°C, and which can become liquid under the conditions of preparation of the composition and has an anisotropic crystalline structure in the solid state. The wax used according to the invention may consist of a polar wax or a non-polar wax or a mixture of these two waxes. "Non-polar" is intended to mean a wax containing only carbon, hydrogen and / or phosphorus atoms, and in particular a hydrocarbon.

[0177] Polar waxes may be chosen from animal waxes, vegetable waxes, and synthetic waxes or silicone waxes containing polar groups such as esters. Thus, mention may be made of carnauba wax, candelilla wax, beeswax (Cera alba), Chinese insect wax (Ericerus pela), Japan wax, sumac wax, montan wax, triesters of C8-C20 acids and glycerol, such as glyceryl tribehenate, in particular acetylated glycol stearate sold by VEVY under the trade name CETACENE, and mixtures thereof. These waxes may be used in particular in pre-dispersed form in oils, as may mixtures of candelilla wax and jojoba oil.

[0178] According to one embodiment, the waxes are present in a content ranging from 0.5% to 50% by weight, preferably from 1% to 25% by weight, preferably from 5% to 10% by weight relative to the total weight of the composition. Preferably, these waxes are vegetable waxes or waxes of vegetable origin.

[0179] “Pasty compounds” are understood to mean lipophilic fatty substances (such as waxes) that are able to undergo a reversible liquid-solid change and have an anisotropic crystalline structure in the solid state, but unlike waxes, they comprise a liquid part and a solid part at a temperature of 23°C.

[0180] According to one embodiment, the pasty compounds are present in a content ranging from 0.5% to 50% by weight, preferably from 1% to 25% by weight, preferably from 5% to 10% by weight relative to the total weight of the composition. These pasty compounds are preferably vegetable fats or fats of vegetable origin, such as shea butter or camellia butter.

[0181] According to one embodiment, the pasty compound is present in a content ranging from 0.5% to 50% by weight, preferably from 1% to 25% by weight, preferably from 5% to 10% by weight relative to the total weight of the composition.

[0182] - One or more gelling agents

[0183] A gelling agent is a compound which, in the presence of a solvent, produces more or less strong macromolecular intermolecular bonds, thereby forming a three-dimensional network which immobilizes the solvent. A gelling agent is also a thickener or rheological agent which acts on the viscosity and flow properties of an aqueous or fatty phase.

[0184] In particular, the gelling agent makes it possible to increase the viscosity of the continuous phase, that is to say to adjust the viscosity of the continuous phase to a value ranging from 100 mPa.s to 20,000 mPa.s.

[0185] The gelling agent may be chosen from polymers of synthetic or plant origin, preferably from polymers of plant origin, chemically modified or not. Thus, it may be chosen from: gums of plant origin, such as gum arabic, konjac, guar gum or their derivatives; gums extracted from algae, such as alginates; gums derived from microbial fermentation, such as xanthan gum, for example the product Keltrol CG (INCI: Xanthan Gum) sold by the company CP KELCO or the product Xanthan Gum FNCS-PC (INCI: Xanthan Gum) sold by the company JUNGBUNZLAUERINTERNATIONAL AG, mannans, scleroglucans or their derivatives; cellulose and its derivatives, such as carboxymethylcellulose or hydroxyethylcellulose; starch and its derivatives, such as natural starch and modified starch, in particular pregelatinized starch, acetylated starch, hydroxypropylated starch, carboxymethylated starch, cationic starch, octenyl succinate starch, cross-linked starch, optionally modified several times; synthetic polymers, such as polyacrylic acid or carbomers and mixtures thereof.

[0186] Among the starches and starch-based blends, mention will be made of Beautéby ST 118 (INCI: carboxymethyl starch), Beautéby ST 720 (INCI: Hydroxypropyl Starch) and Beautéby DS112 (INCI: starch acetate (and) hydroxyethylcellulose (and) xanthan gum), both sold by ROQUETTE.

[0187] Among the carbomers, mention will be made for example of the products Carbopol Ultrez 30 (INCI: Carbomer) or CARBOPOL ETD 2050 polymer (INCI: Carbomer) from the company LUBRIZOL ADVANCED MATERIALS, Inc.

[0188] Mention may also be made of mixtures of gum arabic and xanthan gum, such as the product Solagum AX (INCI: GUM ARABIC (AND) XANTHAN GUM) sold by the company SEPPIC, mixtures of starch and cellulose derivatives, such as the product Beautéby sold by the company ROQUETTE. DS112 (INCI: starch acetate (and) hydroxyethylcellulose (and) xanthan gum).

[0189] The gelling agent may be a mineral gelling agent selected from magnesium silicate and / or aluminum silicate. Examples of such mineral gelling agents are Pure, which is magnesium aluminum silicate.

[0190] According to one embodiment, the gelling agent is present in a content ranging from 0.1% to 50% by weight, preferably from 0.5% to 25% by weight, preferably from 0.3% to 15% by weight relative to the total weight of the composition.

[0191] - One or more binders

[0192] The term "binder" means a compound that imparts increased cohesion to the cosmetic composition. This cohesion can be adjusted depending on the amount and chemical affinity of the binder relative to the ingredients of the cosmetic composition.

[0193] Typically, the binder will be chosen from caprylic / capric triglycerides, such as the product Labrafac CC (INCI: capric / caprylic triglyceride) or cetyl dimethicone (INCI).

[0194] The binder is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1% to 15% by weight, preferably from 5% to 12% by weight, relative to the total weight of the composition.

[0195] - One or more emulsifiers

[0196] The cosmetic composition according to the invention may also comprise one or more oil-in-water (O / W) or water-in-oil (W / O) emulsifiers.

[0197] Oil-in-water (O / W) emulsifiers are emulsifiers with an HLB greater than or equal to 8 and are selected from sorbitan esters (which may be polyethoxylated), glycerol fatty acid esters, sucrose fatty acid esters or polyesters, polyethylene glycol fatty acid esters, polyether-modified polysiloxanes, polyethylene glycol fatty alcohol ethers, alkyl polyglycosides and hydrogenated lecithin, fatty alcohols, sorbitan esters (this list is non-limiting), and mixtures thereof.

[0198] Examples include: Montanov 68 (INCI: Cetearyl Alcohol (and) Cetearyl Glucoside) sold by SEPPIC; Montanov L (INCI: C14-C22 Alcohols and C12-20 Alkyl Glucoside) sold by SEPPIC; Montanov 202 (INCI: Eicosanol (and) Behenyl (and) Arachidyl Glucoside), Citrol GMS 40 (INCI: Glyceryl Stearate) sold by CRODA; or Imwitor 960K (INCI: Glyceryl Stearate) sold by BIESTERFELD; Imwitor 372P (INCI: Stearic Acid Citrate Glyceryl) sold by BIESTERFELD; Glucate SS (INCI: Methyl Glucose Sesquistearate) sold by LUBRIZOL ADVANCEDMATERIALS, Inc; Polystearate (Polyglyceryl-6 Distearate) sold by CRODA, Natragem E145 (INCI: POLYGLYCERIN-4 LAURATE / SUCCINATE (AND) WATER); Span 60 (INCI: SORBITAN STEARATE) marketed by SIGMA ALDRICH.

[0199] Among the sorbitan esters, mention will be made, for example, of the product Span 20.

[0200] Among the fatty alcohols, mention will be made for example of the product sold under the name Promulgen D (INCI: Cetearyl Alcohol (and) Ceteareth-20).

[0201] The W / O emulsifier may advantageously be chosen from an emulsifying system consisting of cyclodextrins and water-in-oil emulsifiers of natural origin, such as the emulsifiers marketed under the trade name Beautéby DS146 sells an emulsifying system.

[0202] The W / O emulsifier may also be selected from an emulsifying system consisting of modified starches and natural gums, such as those manufactured by Roquette Frères under the trade name Beautéby Emulsifying system sold as DS 421.

[0203] Water-in-oil (W / O) emulsifiers are emulsifiers with an HLB of less than 8 and are chosen from non-ethoxylated polyol fatty acid esters, and in particular from non-ethoxylated fatty acid esters of glycerol, non-ethoxylated fatty acid esters of polyglycerol, non-ethoxylated fatty acid esters of sorbitol, non-ethoxylated fatty acid esters of anhydrohexitol, such as in particular isosorbide, mannitol, xylitol, erythritol, maltitol, sucrose, glucose, polydextrose, hydrogenated glucose syrup, dextrin and hydrolyzed starch.

[0204] The emulsifier is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1% to 15% by weight, preferably from 2% to 12% by weight relative to the total weight of the composition.

[0205] - One or more surfactants

[0206] According to one embodiment, the composition according to the invention comprises at least one surfactant selected from ionic surfactants, nonionic surfactants, cationic surfactants, anionic surfactants or amphoteric or zwitterionic surfactants. These surfactants are selected for their detergent and foaming functions.

[0207] According to another embodiment, the composition according to the invention comprises at least one surfactant chosen from anionic surfactants, amphoteric surfactants or zwitterionic surfactants.

[0208] The anionic surfactant is selected from carboxyl anionic surfactants, sulfate anionic surfactants, sulfonate surfactants, phosphate anionic surfactants and mixtures thereof, preferably sulfonate anionic surfactants, carboxyl anionic surfactants and mixtures thereof.

[0209] "Anionic surfactant" is intended to mean a surfactant that contains only anionic groups as ions or ionizable groups. In this specification, under the conditions (e.g., medium, pH) under which the composition of the present invention is used, an entity is described as "anionic" when it has at least one permanent negative charge, or when it can be ionized into a negatively charged entity, and does not contain any cationic charge. "Sulfate-type anionic surfactant" means a surfactant that contains at least one sulfate functional group (-OSO3H or -OSO3 - ) and may optionally further comprise one or more other functional groups derived from an acid, such as a carboxylic acid or carboxylate functional group (-COOH or -COO - ), sulfonate functional group (-SO3H or -SO3 -) and / or phosphate functional groups. For example, alkyl sulfates, alkyl ether sulfates, alkyl amido ether sulfates, alkyl aryl polyether sulfates, monoglyceride sulfates and salts of these compounds are sulfate anionic surfactants. The alkyl groups of these compounds cited by way of example contain 6 to 30 carbon atoms, and the aryl represents a phenyl or benzyl group. These compounds cited by way of example can be polyoxyalkylened, in particular polyoxyethyleneized, and contain 1 to 50 ethylene oxide units. "Non-sulfate anionic surfactants" are intended to mean surfactants that do not fall within the definition of "sulfate anionic surfactants" as defined above.

[0210] According to the present invention, it is also intended to:

[0211] - contains at least one carboxylic acid or carboxylate functional group (-COOH or -COO - ), but does not include sulfonic acid or sulfonate functional groups (-SO3H or -SO3 - ), nor sulfate functional groups (-

[0212] OSO3H or -OSO3 - );

[0213] -sulfonate anionic surfactants contain at least one sulfonic acid or sulfonate functional group (-

[0214] SO3H or -SO3 - ), and may optionally further comprise one or more carboxylic acids or carboxylates (-COOH or -COO - ) and / or phosphate functional groups, but not sulfate functional groups (-OSO3H or -OSO3 - ).

[0215] - Phosphate anionic surfactants contain at least one phosphoric acid or phosphate functional group (-

[0216] OPO3H2 or -OPO3 2- ), but does not include carboxylic acid or carboxylate functional groups (-COOH or -

[0217] COO - ), nor does it include sulfonic acid or sulfonate functional groups (-SO3H or -SO3 - ), nor sulfate functional groups (-OSO3H or -OSO3 - ).

[0218] In other words:

[0219] - Within the meaning of the present invention, it is considered that the compound contains at least one sulfate functional group (-

[0220] OSO3H or -OSO3 - ) and at least one carboxylic acid or carboxylate functional group (-COOH or –

[0221] COO - ) and, unless otherwise specified, are sulfate type anionic surfactants;

[0222] - Within the meaning of the present invention, it is considered that the compound contains at least one sulfate functional group (-

[0223] OSO3H or -OSO3 - ) and at least one sulfonic acid or sulfonate functional group (-SO3H or -

[0224] SO3 - ) and, unless otherwise specified, are sulfate type anionic surfactants;

[0225] - within the meaning of the present invention, it is considered that the monomers contain at least one sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ) and at least one carboxylic acid or carboxylate functional group (-COOH or -

[0226] COO - ) and, unless otherwise specified, are non-sulfate sulfonate anionic surfactants; - within the meaning of the present invention, consider anionic surfactants containing at least one sulfate functional group (-OSO3H or -OSO3 - ) and at least one sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ) and at least one carboxylic acid or carboxylate functional group (-

[0227] COOH or -COO - ) and, unless otherwise specified, are sulfate type anionic surfactants.

[0228] The carboxylic anionic surfactant can be selected from the following compounds: acyl glycinates, acyl lactylates, acyl sarcosinates, acyl glutamates, alkyl-D-galactoside-uronic acid, alkyl ether carboxylic acid, alkyl (aryl) ether carboxylic acid, alkyl (amido) ether carboxylic acid; and salts of these compounds. The alkyl and / or acyl groups of these compounds contain 6 to 30 carbon atoms, more preferably 8 to 28, more preferably 10 to 24, and even more preferably 12 to 22 carbon atoms. The aryl group preferably represents a phenyl or benzyl group. These compounds can be polyoxyalkylene, in particular polyoxyethylene, and then preferably contain 1 to 50 ethylene oxide units, more preferably 2 to 10 ethylene oxide units. C6-C24 alkyl monoesters and polyglycoside-polycarboxylic acids, such as C6-C24 alkyl polyglycoside citrate, C6-C24 alkyl polyglycoside tartrate, and their salts can also be used.

[0229] According to one embodiment, the carboxylic anionic surfactant is selected from:

[0230] - C6-C24 or even C12-C20 acyl glutamates, such as stearoyl glutamate, in particular sodium stearoyl glutamate or disodium cocoyl glutamate, in particular sodium cocoyl glutamate or disodium cocoyl glutamate;

[0231] - acyl sarcosinates, in particular C6-C24, or even C12-C20 acyl sarcosinates, such as cocoyl sarcosinates (in particular sodium cocoyl sarcosinate), lauroyl sarcosinates (in particular sodium lauroyl sarcosinate), palmitoyl sarcosinates (in particular sodium palmitoyl sarcosinate);

[0232] - acyl lactylates, in particular C12-C28, or even C14-C24 acyl lactylates, such as behenyl lactylate (in particular sodium behenyl lactylate), (iso)stearoyl lactylate (in particular sodium (iso)stearoyl lactylate);

[0233] - acyl glycinates, in particular C6-C24 or C12-C20 acyl glycinates, such as cocoyl glycinate, in particular sodium cocoyl glycinate;

[0234] - alkyl (C6-C30) ether carboxylic acids, in particular alkyl (C6-C24) ether carboxylic acids;

[0235] - alkyl (C6-C30) aryl ether carboxylic acids, in particular alkyl (C6-C24) aryl ether carboxylic acids;

[0236] - alkyl (C6-C30) amidoether carboxylic acids, in particular alkyl (C6-C24) amidoether carboxylic acids;

[0237] - and mixtures thereof; in particular in the form of alkali metal or alkaline earth metal salts, ammonium or amino alcohols.

[0238] The anionic sulfonate surfactants may be chosen from the following compounds: alkyl sulfonates, alkylamide sulfonates, alkylaryl sulfonates, C6-C24 alkyl polyglycoside sulfosuccinates, α-olefin sulfonates, kerosene sulfonates, alkyl sulfosuccinates, alkyl ether sulfosuccinates, alkylamide sulfosuccinates, alkyl sulfoacetates, N-acyl taurates, acyl isethionates; alkyl sulfolaurates; and the salts of these compounds; the alkyl group of these compounds contains 6 to 30 carbon atoms, in particular 12 to 28, even better 14 to 24, or even 16 to 22 carbon atoms; the aryl group preferably represents phenyl or benzyl; these compounds may be polyoxyalkylened, in particular polyoxyethyleneated, and in this case preferably contain 1 to 50 ethylene oxide units, better 2 to 10 ethylene oxide units.

[0239] According to one embodiment, the anionic sulfonate surfactant is selected from: C6-C24, in particular C12-C20 alkyl sulfosuccinates, especially lauryl sulfosuccinate; C6-C24, in particular C12-C20 alkyl ether sulfosuccinates; (C6-C24) acyl isethionates, preferably (C12-C18) acyl isethionates; α-olefin sulfonates; and mixtures thereof; in particular in the form of alkali metal or alkaline earth metal, ammonium or amino alcohol salts.

[0240] According to one embodiment, the anionic surfactant can be selected from C6-C24 alkyl monoesters and polyglycoside-dicarboxylic acids, such as alkyl glucoside citrate, alkyl polyglycoside tartrate and alkyl polyglycoside sulfosuccinate, alkyl sulfosuccinamates, acyl isethionates and N-acyl taurates, all of which preferably have 12 to 20 carbon atoms in their alkyl or acyl groups. Another group of anionic surfactants that can be used in the composition of the present invention is acyl lactylates, whose acyl groups contain 8 to 20 carbon atoms. In addition, other examples include alkyl-D-galactosiduronic acid and their salts, as well as polyoxyalkylene (C6-C24 alkyl) ether carboxylic acids, polyoxyalkylene (C6-24 alkyl) (C6-C24 aryl) ether carboxylic acids, polyoxyalkylene (C6-24 alkyl) amido ether carboxylic acids and their salts, in particular those with 2 to 50 ethylene oxide units, and mixtures thereof.

[0241] The phosphate anionic surfactant is selected from: C6-C24 alkyl phosphate esters, especially C12-C20 alkyl phosphate esters; C6-C24 alkyl ether phosphate esters, especially C12-C20 alkyl ether phosphate esters; and mixtures thereof.

[0242] The amphoteric or zwitterionic surfactants may be chosen from secondary, tertiary or quaternary aliphatic amine derivatives, in which the aliphatic radical is a linear or branched chain containing from 8 to 22 carbon atoms and containing at least one anionic group such as a carboxylate, sulfonate, sulfate, phosphate or phosphonate group. Mention may also be made of: alkyl (C8-C20) betaines (e.g. coco betaine), sulfobetaine, alkyl (C8-C20) sulfobetaine, alkyl (C8-C20) amidoalkyl (C3-C8) betaines (e.g. cocoamidopropyl betaine); or alkyl (C8-C20) amidoalkyl (C6-C8) sulfobetaine.

[0243] The cationic surfactant may be selected from cetrimonium chloride sold as Microcare Quat CTC 30 reference.

[0244] The surfactant will be present in the composition according to the invention in a content ranging from 0.1% to 40% by weight, preferably from 0.5% to 30% by weight, preferably from 1% to 20% by weight, preferably from 2% to 12% by weight relative to the total weight of the composition.

[0245] - One or more film formers

[0246] The film former may be chosen from polymers of natural origin, such as hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) or synthetic polymers such as polyvinyl alcohol (PVA), and / or plasticizers other than polyols, such as polyethylene glycol, triethyl citrate, polysorbates, or waxes such as carnauba wax, or hydrogenated castor oil.

[0247] Another plant-derived film former is Beautéby sold by ROQUETTE ST 720 Hydroxypropylated pea starch.

[0248] The film former is present in the composition according to the invention in a content ranging from 0.1% to 20% by weight, preferably from 0.5% to 15% by weight, preferably from 1% to 12% by weight, relative to the total weight of the composition.

[0249] One or more colorants

[0250] The composition according to the invention may also contain at least one dye chosen from water-soluble or fat-soluble dyes, fillers having the effect of coloring and / or opacifying the composition and / or coloring the skin or hair or oral mucosa, such as pigments, mother-of-pearl, lakes (water-soluble dyes adsorbed on an inert mineral carrier) and mixtures thereof. These dyes may optionally be surface-treated with a hydrophobic agent such as silanes, siloxanes, fatty acid soaps, C9-15 fluoroalcohol phosphates, acrylate / polydimethylsiloxane copolymers, C9-15 fluoroalcohol phosphate / silicon mixed copolymers, lecithin, carnauba wax, polyethylene, chitosan and optionally acylatable amino acids such as lauroyl lysine, disodium stearoyl glutamate and aluminum acyl glutamates, phytic acid. Another natural colorant is the caramel colorant Beauté by ROQUETTE. CC 001.

[0251] "Pigment" means white or colored, mineral or organic particles intended to color and / or make a cosmetic composition opaque.

[0252] Among the pigments, mention will be made of mineral or organic, natural or synthetic pigments. Examples of pigments are especially iron, titanium or zinc oxide, and also composite pigments and magenta pigments, pearlescent pigments, interference pigments, photochromic pigments or thermochromic pigments, this list being non-limiting.

[0253] The pigments surface treated with lecithin are UNIPURE WHITE LC981 HLC (INCI: CI 77891 (and) hydrogenated lecithin), UNIPURE YELLOW LC182 HLC (INCI: CI 77492 (and) hydrogenated lecithin), UNIPURE BLACK LC989 HLC (INCI: CI 77499 (and) hydrogenated lecithin), UNIPURE RED LC381 (INCI: CI 77491 (and) hydrogenated lecithin) from Sensient Cosmetic Technologies.

[0254] The pigments surface treated with phytic acid are Unipure White LC 985 PHY (INCI: CI 77891 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Yellow LC 188 PHY (INCI: CI 77492 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Red LC 388 PHY (INCI: CI 77491 (and) Phytic Acid (and) Sodium Hydroxide), Unipure Black LC 998 PHY (INCI: CI 77499 (and) Phytic Acid (and) Sodium Hydroxide) from Sensient Cosmetic Technologies.

[0255] "Perlite" is intended to mean any colored or non-colored particles having a color effect by optical interference.

[0256] Among the perlites, mention will be made of titanium mica covered with metal oxides such as iron oxide or titanium oxide.

[0257] According to one embodiment, the makeup and / or skin care composition according to the invention comprises at least colored particles, preferentially pigments, such as iron oxide pigments and / or perlite.

[0258] The colorant is present in the composition according to the invention in a content ranging from 0.05% to 20% by weight, preferably from 0.1% to 15% by weight, preferably from 0.5% to 12% by weight relative to the total weight of the composition.

[0259] - One or more sensory fillers or powders

[0260] This term is intended to mean particles of any form (especially spherical or lamellar), mineral or organic, which are insoluble in the composition. Examples of organoleptic fillers or powders are talc, boron nitride, starches such as Beautéby sold by ROQUETTE, ST 005 and Beautéby ST 012 granular starch, polyamide, silicone resin, silicone elastomer powder and acrylic polymer powder, in particular poly(methyl methacrylate) powder or styrene acrylate copolymer powder (Sunsphere Powders from Dow).

[0261] The filler is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1% to 15% by weight, preferably from 3% to 12% by weight, relative to the total weight of the composition.

[0262] One or more sensory agents

[0263] Sensory agents can be used to modify the sensory characteristics of cosmetic or dermatological compositions, making them more comfortable to use on the skin. Sensory agents can be selected from modified starches, such as carboxymethylated starches, for example Beauté by Roquette ST 118 from Roquette, silicon dioxide or talc, or mixtures thereof. These sensory agents provide a soft touch to solid compositions, or a buffering effect to liquid or gel-form compositions.

[0264] The sensory agents are present in the composition according to the invention in a content ranging from 0.1% to 20% by weight, preferably from 1% to 15% by weight, preferably from 3% to 12% by weight, relative to the total weight of the composition.

[0265] - One or more active ingredients

[0266] The cosmetic composition may contain, in addition to the hyperbranched dextrin, one or more active ingredients.

[0267] These active ingredients can be of a wide range of chemical types, since, as the applicant has noted, hyperbranched dextrins, preferentially hyperbranched hydrogenated dextrins, are fairly inert, have low reactivity and excellent compatibility with most active ingredients used in cosmetic or even dermatological compositions. These active ingredients can be selected from moisturizers, emollients, film formers, barrier agents, antifouling agents, firming agents, anti-aging agents, antioxidants, exfoliants, collagen stimulators, anti-acne agents, sebum reducing agents, blood circulation stimulators, fresheners, antibacterial agents, antifungal agents, anti-inflammatory agents, soothing agents, anti-irritants, healing agents, slimming agents, dyes, colorants, oil-control agents and fragrances.

[0268] Among the soothing agents, those extracted from plants are preferentially used. By way of illustration, C-glycosides (such as those disclosed in FR2902998) are used as soothing agents. Natural products such as ceramides, sweet almond oil or chamomile oil, extracts of mimosa tenuiflora (tepezcohuite), aloe vera, liquorice (glycyrrhetinic acid), calendula, St. John's wort, oats, linden, magnolia, marshmallow or mallow are also particularly effective soothing agents.

[0269] Preferentially, the hyperbranched, preferably hyperbranched hydrogenated dextrin can be combined with an anti-inflammatory cosmetic active ingredient or another soothing active ingredient.

[0270] The active ingredient is present in the composition according to the invention in a content ranging from 0.05% to 20% by weight, preferably from 0.1% to 10% by weight, preferably from 0.5% to 6% by weight, relative to the total weight of the composition.

[0271] Example

[0272] Example 1: Clinical study of discomfort induced by sodium lauryl sulfate

[0273] The aim of this study was to determine the molecular weight of hyperbranched hydrogenated dextrins (based on the reference material of Roquette). The effect of the patch (sold as SURFACE® HM 06) on the discomfort caused by exposure of the inner forearm skin of volunteers to the skin-aggressive product sodium lauryl sulfate (SLS) applied via a patch at a concentration of 10% in water.

[0274] Volunteers and Products

[0275] This non-invasive single center study was conducted on forty male volunteers aged between 30 and 55 years with sensitive skin (based on self-report). The inclusion criteria for the volunteers are shown in the table.

[0276] [Table 1]

[0277] standard gender male Phenotype I to III age From 30 to 55 years old (divided into 3 homogeneous average groups) Sensitive skin Yes, based on volunteer reports

[0278] The volunteers were divided into two homogeneous groups of 20 volunteers and each group received the lotion according to the table below.

[0279] Lotion composition

[0280] [Table 2]

[0281]

[0282] Study plan

[0283] At the beginning of the study (Day 0), the SLS 10% patch was placed on two demarcated areas on each volunteer's forearm. The volunteers kept the patch for 20 hours and removed it 4 hours before the self-assessment on Day 1, so that on Day 1, self-assessment was performed on both forearms of all volunteers. Immediately after the measurement on Day 1, each group applied its lotion to the area exposed to the SLS patch on the right forearm, which was the treated area, and then self-assessed 5 minutes, 10 minutes and 30 minutes after the application. The left forearm was not treated with any lotion; this is an untreated area.

[0284] Volunteers applied the same lotion to the SLS-exposed area of ​​their right forearm every night from day 1 to day 6. The left forearm received no treatment. On days 2, 3, 4, and 7, the lotion-treated area and the untreated area were self-assessed.

[0285] self assessment

[0286] The volunteers rated their own feelings of discomfort, warmth and tightness on the treated and untreated areas on a semi-structured scale ranging from 1 to 10, with 1 corresponding to "not intense" and 10 corresponding to "very intense".

[0287] result

[0288] [Table 3]

[0289]

[0290] This table depicts the mean values ​​of self-assessment of fever sensation.

[0291] [Table 4]

[0292]

[0293] The table shows the mean values ​​for the self-assessment of tightness sensation.

[0294] In order to compare the changes in the sensations of heating and tightness between the different groups, the changes in these sensations were calculated between the different measurement times, e.g. for the treated areas of the skin:

[0295] [Mathematical operation 1]

[0296] For both groups, ΔTreatment((Day x)-Day 1)=(sensation assessed in the treated area on Day x)-(sensation assessed in the treated area on Day 1).

[0297] [Table 5]

[0298]

[0299] The table depicts the mean changes in the sensations of warmth and tightness over time between treated and untreated areas of the skin.

[0300] HM 06 hyperbranched dextrin reduced SLS-induced heating sensation as early as 10 minutes compared to the placebo group, and this reduction was increased and maintained up to 7 days.

[0301] HM 06 hyperbranched dextrin reduced SLS-induced tightness as early as 5 minutes compared to the placebo group, and this reduction was maintained for up to 4 days on average.

[0302] By applying HM 06 hyperbranched dextrin reduced the sensation of skin heating and tightness, indicating that this dextrin was able to soothe the skin reaction caused by SLS 10% patch. HM 06 Hyperbranched Hydrogenated Dextrin is soothing.

[0303] Example 2: Formulation of a cosmetic product containing hyperbranched hydrogenated dextrin according to the object of the present application

[0304] Roquette HM 06 hyperbranched hydrogenated dextrin, due to its specific chemical properties previously disclosed herein, as the applicant has observed, has very little or no reactivity with most active ingredients used in cosmetic and dermatological compositions, and is therefore highly compatible and easy to use for the formulator.

[0305] In fact, it can function as a demulcent in a wide variety of formulations, such as those listed below and given by way of illustration and not limitation.

[0306] After sun cream

[0307] [Table 6]

[0308]

[0309] Preparation protocol: Prepare phase A and phase B in two separate beakers at 70°C. Then emulsify phase B in phase A under high shear stirring for 10 minutes. Then cool to 20°C + / - 2°C. Add phase C under stirring followed by phase D. Finally, adjust the pH to 6. A white cream is obtained with a Brookfield viscosity of 3500 mPa.s + / - 700 (spindle 4, 20 rpm).

[0310] After shave gel

[0311] [Table 7]

[0312]

[0313] Preparation: Isosorbide, Nutriose

[0314] HMC 06 was premixed in the required amount of water for phase A and then Beauté by Roquette DS112 starch was dispersed at 80° C. for 30 to 40 minutes. Phases B1 and B2 were then added successively and the pH was adjusted to 6. A translucent gel was obtained with a Brookfield viscosity of 3500 mPa.s + / - 700 (spindle 4, 20 rpm).

[0315] Soothing Oil-in-Water Emulsion

[0316] [Table 8]

[0317]

[0318] Preparation protocol: Add Nutriose HMC 06 to half the volume of water required for the formulation at 45°C, stirring at 500 rpm with a deflocculation centrifuge until a clear solution is obtained. In addition, mix the ingredients of phase A2 in half the volume of water required for the formulation under stirring at 500 to 1000 rpm. Then mix phase A1 with phase A2, add phase A3 under stirring at 1500 rpm for 10 minutes. Phase B is also prepared by heating to 45°C. Then emulsify phase B in phase A1+A2+A3 at 45°C under vigorous stirring at 2000 to 3000 rpm for 15 minutes. Cool it to 20°C+ / -2°C, add phases C, D, E and F successively under stirring at 500 rpm, and adjust the pH to 5.3+ / -0.2. A blue emulsion with a Brookfield viscosity of 4500 to 5500 mPa.s (spindle No. 3, 20 rpm) was obtained.

[0319] Soothing Repair Hand Cream

[0320] [Table 9]

[0321]

[0322] Preparation protocol: Nutriose HMC 06 is added to the volume of water required for the formulation at 45°C, stirring with a deflocculation centrifuge at 500 rpm until a clear solution is obtained, then cooled to 20°C + / - 2°C. Beauté by Roquette DS 421 is then dispersed in phase A, stirring with a deflocculation centrifuge at 1000 rpm for about 10 minutes to hydrate the ingredient, which is confirmed by visual observation of its opalescence. Phase C is prepared separately. Phase C is slowly added to phases A+B at ambient temperature (20°C + / - 2°C) while stirring with a deflocculation centrifuge at 2000 to 3000 rpm, then kept stirring for 10 minutes. Finally, phase D is added under stirring at 1000 to 2000 rpm, then the pH is adjusted to 4.5-4.7. A yellow cream is obtained with a Brookfield viscosity of 8800 mPa.s (spindle No. 3, 20 rpm).

[0323] Soothing Cleansing Cream (TO-027-001)

[0324] [Table 10]

[0325]

[0326] Soothing Hair Conditioning Gel (HC-040-001)

[0327] [Table 11]

[0328]

[0329] Soothing Hair Conditioning Cream (HC-040-002)

[0330] [Table 12]

[0331]

[0332] Soothing Elixir (SC-073-003)

[0333] [Table 13]

[0334]

[0335] Sulfated surfactant-free shampoo (HC-031-002)

[0336] [Table 14]

[0337]

[0338] Soothing Shampoo (HC-025-008)

[0339] [Table 15]

[0340]

[0341] After Sun Cream(SC-073-011)

[0342] [Table 16]

[0343]

[0344] Preparation: Nutriose 06 Disperse in water and Beautéby with gentle stirring PO070 sorbitol mixture. Then add Beautéby DS 112, and heat the product to 80°C with medium stirring using a deflocculating paddle, and keep stirring at this temperature for 40 minutes to obtain a uniform gel. Cool to 25°C-30°C with gentle stirring. Then add phase B with moderate stirring, and keep stirring for 5 minutes. Then add phase C with moderate stirring, followed by phase D with moderate stirring, and stir for 5 minutes. Add phase E with gentle stirring. Finally, adjust the pH to 5 using phase F.

[0345] Sun Blocking Rod (SU-024-018)

[0346] [Table 17]

[0347]

[0348] Preparation protocol: The ingredients of phase A are mixed under stirring and heated to 80°C. Phase B is then prepared under vigorous stirring using a deflocculating paddle (2000 rpm) until all ingredients are well dispersed. Phase A is cooled to 60°C and then added to phase B under gentle stirring. Maintaining at 60°C, the mixture is poured into a mold and then allowed to cool to 20°C. A solid composition in the form of a stick is obtained.

Claims

1. A non-therapeutic use of a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, as a soothing agent, Features The dextrin contains at least 5% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

2. The non-therapeutic use according to claim 1, Features The dextrin has: - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 42% to 50% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

3. The non-therapeutic use according to claim 1, Features The dextrin has: - at least 5% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% - no more than 70% of 1-4 glycosidic bonds, preferably no more than 60% and most preferably no more than 50% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - at least 1% of 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%, - At least 1% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

4. The non-therapeutic use according to one of claims 1 to 3, Features The soothing agent is a medicament for soothing skin reactions and / or oral mucosal reactions.

5. A non-therapeutic use of a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, for preventing or reducing or eliminating skin reactions and / or oral mucosal reactions, Features The dextrin contains at least 5% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

6. The non-therapeutic use according to claim 5, Features The dextrin has: - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 42% to 50% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

7. The non-therapeutic use according to claim 5, Features The dextrin has: - at least 5% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% - no more than 70% of 1-4 glycosidic bonds, preferably no more than 60% and most preferably no more than 50% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - at least 1% of 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%, - At least 1% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

8. The non-therapeutic use according to any one of claims 1 to 7, Features The skin reaction is a skin reaction of the skin and / or scalp and is selected from warmth, tightness, tingling, numbness, itching.

9. The non-therapeutic use according to any one of claims 1 to 7, Features The oral mucosal reaction is selected from the group consisting of burning, heat, tightness, tingling, numbness and itching.

10. The non-therapeutic use according to any one of claims 1 to 9, Features The skin and / or scalp and / or oral mucosa are sensitive.

11. The non-therapeutic use according to any one of claims 1 to 10, Features The skin reaction and / or oral mucosal reaction is induced by endogenous and / or exogenous stress.

12. The non-therapeutic use according to any one of claims 1 to 11, Features The exogenous stress is selected from the group consisting of chemicals or formulation components, mechanical insults, environmental factors, thermal insults, foods and beverages.

13. The non-therapeutic use according to any one of claims 1 to 12, Features The endogenous stress is selected from hormone secretion, age, stress and sweating.

14. A method for soothing non-therapeutic care of the skin and / or scalp and / or oral mucosa, said method comprising applying a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, to said skin and / or scalp and / or oral mucosa, Features The dextrin contains at least 5% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

15. The non-therapeutic care method according to claim 14, Features The dextrin has: - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 42% to 50% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

16. A non-therapeutic care method according to claim 14 or 15, comprising applying a hyperbranched dextrin, preferably a hydrogenated hyperbranched dextrin, to the skin and / or scalp and / or oral mucosa showing one or more skin reactions.

17. The non-therapeutic care method according to claim 14 or 15, Features Hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, are applied to the skin and / or scalp and / or oral mucosa in preparation for the application of cosmetic or dermatological treatments or endogenous and / or exogenous stressors.

18. A cosmetic composition comprising hyperbranched dextrins, preferably hydrogenated hyperbranched dextrins, in a cosmetically acceptable medium. Features The dextrin contains at least 5% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.

19. The cosmetic composition according to claim 18, Features The dextrin has: - at least 5% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15% - no more than 70% of 1-4 glycosidic bonds, preferably no more than 60% and most preferably no more than 50% relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - at least 1% of 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%, - At least 1% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.

20. The cosmetic composition according to claim 18, Features The dextrin has: - 5% to 40% 1-6 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 42% to 50% 1-4 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-3 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds, - 1% to 20% 1-2 glycosidic bonds relative to the sum of 1-2 bonds, 1-3 bonds, 1-4 bonds and 1-6 bonds.